BARKER SAM L 4

What Happened
Sam L. Barker, a director of Lexicon Pharmaceuticals (LXRX), was granted two derivative equity awards on 2026-05-01: 35,714 units and 43,478 units, each reported at $0.00 acquisition price, for a total of 79,192 underlying shares. These were reported on a Form 4 filed 2026-05-04. Because these are grants (awards), no cash was paid by the insider.

Key Details

• Transaction date: 2026-05-01; Form 4 filed: 2026-05-04 (appears timely).
• Awards: 35,714 and 43,478 derivative units; reported acquisition price $0.00. Total underlying shares = 79,192.
• Shares owned after transaction: not disclosed on the supplied summary of the Form 4.
• Footnotes: F1–F2 indicate a restricted stock unit (RSU) that vests 100% on the first anniversary and converts 1:1 to common stock; F3 indicates an option that vests one‑third on each of the first three anniversaries.
• Transaction code: "A" — grant/award (derivative security).

Context
These awards are grants of equity-linked instruments (RSU and option per footnotes). RSUs convert to shares upon vesting; the option vests over three years per F3. Grants do not signal an immediate purchase or sale — they represent future potential ownership if vesting conditions are met. No immediate cashless exercise or sale was reported in this filing.